Background and purpose: Although CB 1 receptor activation evokes neuroprotection in response to cannabinoids, some cannabinoids have been reported to be peroxisome proliferator activated receptor (PPAR) ligands, offering an alternative protective mechanism. We have, therefore, investigated the ability of a range of cannabinoids to activate PPARa and for N-oleoylethanolamine (OEA), an endogenous cannabinoid-like compound (ECL), to evoke neuroprotection. Experimental approach: Assays of PPARa occupancy and gene transactivation potential were conducted in cell-free and transfected HeLa cell preparations, respectively. In vivo estimates of PPARa activation through fat mobilization and gene transcription were conducted in mice. Neuroprotection in vivo was investigated in wild-type and PPARa gene-disrupted mice. Key results: The ECLs OEA, anandamide, noladin ether and virodhamine were found to bind to the purified PPARa ligand binding domain and to increase PPARa-driven transcriptional activity. The high affinity synthetic CB 1/2 cannabinoid agonist WIN 55212-2 bound to PPARa equipotently with the PPARa agonist fenofibrate, and stimulated PPARa-mediated gene transcription. The phytocannabinoid D 9 tetrahydrocannabinol was without effect. OEA and WIN 55212-2 induced lipolysis in vivo, while OEA pre-treatment reduced infarct volume from middle cerebral artery occlusion in wild-type, but not in PPARa-null mice. OEA treatment also led to increased expression of the NFkB-inhibitory protein, IkB, in mouse cerebral cortex, while expression of the NFkB-regulated protein COX-2 was inhibited. Conclusions and implications: These data demonstrate the potential for a range of cannabinoid compounds, of diverse structures, to activate PPARa and suggest that at least some of the neuroprotective properties of these agents could be mediated by nuclear receptor activation.
Introduction
The cannabinoids are a structurally diverse family of compounds with a large number of different biological targets. Many of their effects are mediated by CB 1 and CB 2 receptors, two 7-transmembrane G protein-coupled receptors that have been cloned and well characterized (Howlett, 2002; Di Marzo et al., 2004; Mackie, 2006) , although several studies have produced evidence supporting the existence of other non-CB 1 /non-CB 2 G protein-coupled receptors (Jarai et al., 1999; Breivogel et al., 2001; Hajos et al., 2001) , possibly including the orphan GPR55 (Baker et al., 2006) . Cannabinoids have been reported to stimulate other non-G proteincoupled receptors, the best characterized of these being the transient receptor potential vanilloid receptor 1 (TRPV1) or vanilloid receptor channel, which is activated by endogenous cannabinoids such as anandamide. Indeed, TRPV1 has been proposed to be the ionotropic cannabinoid receptor (Di Marzo et al., 2002) .
In addition to these cell-surface cannabinoid receptors, there is growing evidence that the intracellular peroxisome proliferator-activated receptors (PPARs) are cannabinoid targets. The PPARs function as lipid-sensing receptors and, through the activation or repression of large sets of particular genes, they are intimately involved in the regulation of crucial metabolic events (Berger et al., 2005) . The endogenous cannabinoid system is also involved in the control of energy balance as demonstrated by reductions in calorie intake, total fat mass and body weight in CB 1 -null mice (Cota et al., 2003b) . PPARg has recently been proposed as a cannabinoid target (Burstein, 2005) and we have also recently demonstrated that some of the longer term vascular effects of the plant cannabinoid tetrahydrocannabinol (D 9 THC) are mediated by this entity (O'Sullivan et al., 2005) . Some effects of endogenous cannabinoid-like molecules (ECLs) appear to be due to activation of other PPARs; regulation of appetite and lipolysis by N-oleoylethanolamine (OEA) and the anti-inflammatory effects of N-palmitoylethanolamine have been demonstrated to occur via interaction with PPARa (Fu et al., 2003; Guzman et al., 2004; Lo Verme et al., 2005) .
In this study, we have sought to determine whether cannabinoids with radically distinct structures interact with PPARa by assessing ligand binding and receptor activation in vitro. Since the selective PPARa ligand fenofibrate has been shown to provide neuroprotection in a mouse model of cerebral ischaemia (Deplanque et al., 2003) , we have also examined the potential neuroprotective effects of the endogenous cannabinoid/PPARa agonist OEA in vivo.
The results presented demonstrate that a number of cannabinoid compounds are functionally effective PPARa agonists and that OEA has neuroprotective properties via PPARa activation. This indicates an additional mechanism by which the diverse effects of this physiologically and therapeutically important group of agents are mediated.
Methods
In vitro studies Purification of the mPPARa-LBD-GST fusion protein. A mouse PPARa cDNA fragment was amplified from cDNA generated from mouse liver mRNA by reverse transcription (upper primer: 5 0 -CTGCCTTCCCTGTGAACTGACGTTTGTGGC-3 0 ; lower primer: 5 0 -TGTGCAAATCCCTGCTCTCCTGTATGGG GC-3 0 ). The cDNA encoding the mouse PPARa ligandbinding domain (LBD) with a deletion of the N-terminal A/B domain and mouse PPARa DNA-binding domain (amino acids 198-468) were ligated into pGEX-4T-1, a glutathione S-transferase (GST)-tagged bacterial expression vector, to generate the plasmid pGEX-mPPAR-LBD. The sequenceconfirmed plasmid was transformed into Escherichia coli strain XL-10 and bacteria containing pGEX-mPPAR-LBD were cultured to OD 600 0.6-0.8 at 37 1C. Expression of the GST-tagged LBD was induced with 0.2 mM isopropyl b-D-1-thiogalactopyranoside at 28 1C for 5 h. Lysates from these cultures were prepared and the expressed fusion protein was purified by glutathione-Sepharose 4B (Amersham Pharmacia, Chalfont St Giles, UK) with an elution buffer containing 20 mM reduced glutathione and 0.25% 3-(3-cholamidopropyl)dimethylammonio]-propanesulphonic acid in Trisbuffered saline buffer (10 mM Tris, 150 mM NaCl, pH 7.8). The purity of the resulting protein was assessed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis followed by Coomassie blue staining and by immunoblotting using an anti-PPARa antibody (Biomol, Exeter, UK). Protein concentrations were determined by the Coomassie blue method (BioRad, Hemel Hempsted, UK).
Binding of cis-parinaric acid. Binding of cis-parinaric acid (CPA) to the mPPARa LBD was monitored by measuring the enhanced fluorescence of the probe in the presence of the LBD protein (Causevic et al., 1999) . Purified protein was diluted to 1 mM in Tris-buffered saline buffer; diluted proteins were combined with increasing quantities of CPA from a concentrated solution (3 mM) in ethanol. Protein and probe mixtures, 330 ml per well, were loaded into 96-well solid black-walled microplates. Fluorescence output (excitation, 315 nm; emission, 415 nm) was measured by reading the plate from the top using a FlexStation II plate reader (Molecular Devices, Sunnyvale, California, USA) at 25 1C. Background fluorescence, due to CPA in the absence of protein, was subtracted from each data point. The apparent K d value for CPA was calculated from LBD saturation curves using GraphPad Prism (Figure 1 ). The affinities of nonfluorescent ligands for the LBD were calculated as IC 50 values (concentrations reducing CPA/LBD fluorescence by 50%) from competition curves. Increasing concentrations of ligand were incubated in the presence of 1 mM mPPARa LBD and 2 mM CPA. Fluorescence was measured as above and corrected for background (drugs and CPA only).
Reporter gene activity of PPARa. Full-length mouse PPARa, including both DNA-binding domain and LBD, was ligated into pcDNA3.1/Zeo þ to generate the plasmid pcDNAwmPPAR. HeLa cells were maintained in Dulbecco's modified Eagle's medium with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 50 mg ml À1 penicillin and 50 mg ml À1 streptomycin at 37 1C, 5% CO 2 . HeLa cells, 60-70% confluent, in six-well plates were transiently transfected with pcDNAwmPPAR (0.5 mg) together with the reporter plasmid PPRE (1 mg per well). The reporter contains three PPARbinding sites linked to a promoter controlling the gene for firefly luciferase. Transient transfection was carried out by the polyethyleneimine method with the ratio nitrogen (N) to DNA phosphate (P) of N/P ¼ 15 (Boussif et al., 1995; Turk et al., 2004) . Immediately before transfection, cells were rinsed with phosphate-buffered saline (PBS) and supplemented with fresh serum-free culture medium. The plasmid DNA and the desired amount of polyethyleneimine polymer solution were each diluted in 150 mM NaCl and vortexed. The two solutions were then mixed and vortexed. After 20 min, the transfection mixture was added to the cells. After 4 h incubation, the medium was supplemented with 10% heat-inactivated fetal bovine serum; 16 h later, the complete medium was replaced with new Dulbecco's modified Eagle's medium with 0.5% heat-inactivated fetal bovine serum. Then 12 h later, appropriate amounts of drugs were added and cells were collected after another 15-16 h. Luciferase gene expression was monitored by luminometry using a commercial kit (Promega, Southampton, UK ) for 1 h at room temperature, followed by a 60 min incubation at room temperature, or overnight at 4 1C, with primary antibody in 5% w v ). Membranes were rinsed rapidly three times, followed by a further three 20 min washes in PBS Tween, before incubation for 1 h with the appropriate secondary antibody in 1% w v À1 skimmed milk powder, PBS Tween. After being rinsed three times (20 min washes in PBS Tween), membranes were developed using the enhanced chemiluminescence western blotting detection system (Amersham Pharmacia, Chalfont St Giles, UK) according to the manufacturer's protocol. Immunoblots were scanned and digitized images were quantified by densitometry using AIDA 2.0 software; levels of immunoreactivity were compared with actin immunoreactivity from the same samples.
In vivo studies Mouse middle cerebral artery occlusion. Male mice (wild-type C57BL/6 or PPARa knockouts C57BL/6 PPARa À/À , the latter obtained from Jackson Labs, Bar Harbor Maine, USA) were treated for 3 consecutive days with drugs (10 mg kg À1 per day i.p.). Twenty four hours later, cerebral ischaemia was induced by occlusion of the right middle cerebral artery as described previously (Gibson and Murphy, 2004) . Following 60 min of middle cerebral artery occlusion (MCAO), mice were anaesthetized with 4% isoflurane (in an NO 2 /O 2 70/30 mixture) and maintained by inhalation of 1.5% isoflurane. The occluding filament was withdrawn gently back into the common carotid artery to allow reperfusion to take place. In one experiment, mice were given a single injection of OEA at the end of the occlusion period. Final lesion volume was determined histologically 48 h later. Mice were killed by an overdose of pentobarbitone (i.p.) and the brains were sectioned into five 2-mm coronal slices using a mouse brain matrix (ASI Instruments, Warren, MI, USA). To quantify ischaemic damage, coronal slices were stained with 2% w v À1 2,3,5-triphenyltetrazolium chloride in saline for 30 min at room temperature in the dark. The area of infarction was measured on the posterior surface of each coronal section using a BioQuant IV image analysis system (Bioquant Inc., Ann Arbor, MI, USA). Because of substantial hemispheric swelling following ischaemia, infarct areas were calculated by a subtractive method in which the overestimation of infarct area due to the contribution of oedema is avoided. The infarcted area of the right (ischaemic) hemisphere was determined by subtracting the non-infarcted area of the right hemisphere from the total area of the left (uninfarcted) hemisphere. Total infarct volume was then determined by multiplying the area of infarct for each slice by the slice thickness (2 mm) and summing for all slices.
Stimulation of lipolysis. Lipolysis in vivo was assessed following injection of mice with 10 mg kg À1 (i.p.) test compound.
Drugs were dissolved in dimethylsulphoxide (DMSO) to 10 mM, then diluted in normal saline to the appropriate concentration. The injection volume was 300 ml per mouse, with no animal receiving in excess of 25 ml DMSO. Blood was collected 1 h later in lithium heparin tubes (BD Biosciences, Oxford, UK), adding ethylene glycol tetraacetic acid to 1 mM and then centrifuging carefully at 2500 g for 20 min. Plasma was carefully transferred into new Eppendorf tubes and blood plasma-free fatty acids (FFA) were measured with a commercial kit (Wako Chemicals, Richmond, Vancouver, USA, 994-75409).
Animals. This study was conducted in accordance with the UK Animals (Scientific Procedures) Act, 1986 (Project Licences 40/2206 and PP 40/2715). All mice were housed in a pathogen-free facility at the University of Nottingham with access to food and water ad libitum. PPARa-null mice were expressed on a C57 background, while wild-type mice (C57, male, 20-35 g) were bred at the Biomedical Services Unit, University of Nottingham. Animals were group-housed (3-4 per cage) and lighting was provided from 0700 to 1900 hours, with all procedures carried out between 0800 and 1700 hours. 
Results
In vitro binding to the mPPARa ligand-binding domain cis-Parinaric acid bound to the GST-mouse PPARa-LBD fusion protein in a saturable fashion with a calculated K d value of 5.4 mM (Figure 1c) . Representatives of each of the major structural cannabinoid groups were assessed for their ability to bind to the LBD. The synthetic cannabinoid, WIN 55212-2, decreased the fluorescence of CPA in the presence of PPARa LBD in a concentration-dependent fashion with an apparent affinity slightly higher than that of the standard PPARa agonist fenofibrate (20 and 40 mM, respectively), while, the phytocannabinoid D 9 THC failed to alter CPA binding to PPARa LBD at concentrations up to 30 mM ( Figure 1a) . OEA has been shown to be a PPARa ligand (Fu et al., 2003) and it was found to decrease CPA-evoked fluorescence with an affinity between that of WIN 55212-2 and fenofibrate (EC 50 value B30 mM). The putative endocannabinoids, anandamide, noladin ether and virodhamine all appeared to bind to PPARa with broadly similar affinities having a rank order of noladin ether4anandamide4virodh-amine (EC 50 values 10-30 mM, Figure 1b) .
Activation of the mPPARa in vitro
Although the high-affinity CB 1 /CB 2 receptor agonist, WIN 55212-2 showed similar affinity at the PPARa LBD compared to the PPARa ligand fenofibrate (Figure 1a ), its efficacy with regard to PPARa transcriptional activity was apparently much lower (Figure 2) , although its maximum effect might have been compromised by toxicity at concentrations higher than 1 mM (data not shown). As expected, the phytocannabinoid, D 9 THC, which did not bind to the PPARa LBD in the CPA displacement assay (Figure 1a ), failed to alter PPARa transcriptional activity (Figure 2) . At 10 mM, the fatty acid ethanolamides, OEA and anandamide both evoked significant increases in luciferase gene expression (Figure 2) . However, in a similar manner to WIN 55212-2, anandamide reduced the viability of HeLa cells at a high concentration (410 mM) in our transient transfection system as measured by total protein concentrations (data not shown). Although they have been studied less than anandamide, noladin ether and virodhamine are putative endocannabinoids and both of them were found to double the PPARa-driven transcription at 10 mM (Figure 2 ). Although structurally similar to anandamide, their toxicity for HeLa cells was much less as measured by total protein concentrations (data not shown). Investigation of the effects of WIN 55212-2 and anandamide in reporter gene assays using other host cells (HEK293 human embryonic kidney and Chinese hamster ovary fibroblast cells) indicated a much greater tolerance, indicating that these effects on cell viability are not ubiquitous (data not shown).
Cannabinoid effects in vivo Intraperitoneal administration of OEA as a solution (8% v v À1 DMSO) evoked no visible behavioural effects in treated mice. In the mouse MCAO model of cerebral ischaemia, a single 1-h treatment with OEA at the end of the occlusion period had no effect on lesion size (data not shown). However, both fenofibrate and OEA treatments were found to reduce infarct volume significantly following 3 days of pre-treatment (Figure 3a ). For example, lesion volume in untreated animals was 2773 mm 3 , compared to 1871 mm 3 following OEA administration. This protective effect appeared to be PPARa-mediated since it was not apparent in the PPARa-null mice (Figure 3b ). Lesion volumes in the vehicle-treated knockout animals were also not significantly different from the wild-type controls (Figure 3b ). OEA and WIN 55212-2 (at 10 mg kg
À1
) were found to increase significantly plasma FFA levels after 1 h of exposure (Figure 4a ). The putative endocannabinoid noladin ether, which showed increased affinity in binding to the PPARa in vitro compared to OEA (Figure 1b) , although with comparable efficacy (Figure 2) , also appeared to increase lipolysis in wild-type mice, but this effect failed to reach statistical significance (Figure 4a ).
Since PPARa pre-activation by OEA was found to be neuroprotective, the involvement of two PPARa-regulated genes known to be involved in the control of inflammation, were investigated in the mouse cerebral cortex. The NF-kB pathway, which plays an important role in the inflammatory response, was assessed by measuring expression of its inhibitory protein IkBa by immunoblotting. The cerebral cortices of OEA-pre-treated mice were found to express almost three times the levels of IkBa compared to tissue from vehicle-treated animals ( Figure 4b ). The expression of the inflammatory marker enzyme COX-2 was also found to be reduced significantly in the cerebral cortex after OEA pretreatment (Figure 4b ).
Discussion
In this study, we describe a novel mechanism for cannabinoid-induced neuroprotection in vivo, via activation of the nuclear receptor, PPARa. Repeated dosing with the putative endocannabinoid OEA increased central nervous system (CNS) levels of the anti-inflammatory mediator IkBa, while decreasing the pro-inflammatory enzyme COX-2, and also reduced infarct volume following MCAO in a PPARadependent manner.
Functional targets of endocannabinoids
The term cannabinoid describes a structurally diverse group of compounds that can potentially bind to (at least) two 7-transmembrane cannabinoid receptors (CB 1 and CB 2 ). Although many of the physiological responses to cannabinoids, such as alterations in cognition and memory, euphoria, immobility, analgesia, hypothermia and sedation (Howlett, 1995) , are generally thought to be due to CB receptors, studies with CB 1 , CB 2 or CB 1 /CB 2 double-knockout mice * * * * * * * * * * * Luciferase activity (RLU/mg protein) Figure 2 The effects of selected synthetic and endogenous compounds on PPARa-mediated transcriptional activity. HeLa cells were transiently co-transfected with PPARa and the PPRE-luc reporter gene constructs. Thereafter the cells were exposed to ligands overnight and the generation of luciferase estimated using a commercial luminometry kit. With the exception of WIN 55212-2 (WIN, 1 mM), ligands were present at 10 mM. Data are means7s.e.mean of three experiments conducted in sextuplicate. *Po0.05, **Po0.01 vs control, one-way analysis of variance with post hoc Dunnett's multiple comparison test. PPARa, peroxisome proliferator-activated receptor-a.
Cannabinoid neuroprotection by activation of PPARa Y Sun et al have revealed some non-CB receptor-mediated responses to cannabinoids both in the CNS and periphery . Although perhaps not a direct agonist of cannabinoid receptors (Lambert et al., 1999) , being a structural analogue of anandamide, OEA has cannabimimetic effects by competing with anandamide for the endocannabinoid-metabolizing enzyme, fatty acid amide hydrolase (Jonsson et al., 2001) and can be considered an ECL. OEA has recently been shown to be the endogenous ligand of an 'orphan' receptor GPR119, which appears to be localized primarily to gut-associated organs, with some CNS expression (Overton et al., 2006) . OEA activity at the nuclear receptor PPARa has also been demonstrated recently; OEA was observed to regulate feeding behaviour and body weight and to induce lipolysis via PPARa-dependent mechanisms (Fu et al., 2003; Guzman et al., 2004) . Because of the possibility that other cannabinoids might share this last property with OEA, the main aim of the present study was to test the affinity and efficacy of different cannabinoids at PPARa and to investigate physiological consequences of in vivo exposure to such agents.
PPARa activity of synthetic and endogenous cannabinoids
By the use of multiple in vitro and in vivo assays, OEA was confirmed as a bona fide PPARa ligand. Indeed, in the in-vitro binding assay, OEA showed a similar potency to fenofibrate Wild-type C57 mice were exposed to 60 min occlusion following three daily injections of OEA (10 mg kg
À1
, n ¼ 4), fenofibrate (10 mg kg À1 , n ¼ 4) or vehicle (0.1 ml 10% DMSO, n ¼ 5). (b) PPAR-null or wild-type littermate C57 mice were exposed to 60 min occlusion following three daily injections of OEA (10 mg kg À1 day À1 , n ¼ 5 and 4 for wt and PPARa-null, respectively) or vehicle (0.1 ml 10% DMSO, n ¼ 6 and 4 for wt and PPARa-null, respectively). *Po0.05, **Po0.01 vs vehicle treatment, one-way analysis of variance with Dunnett's multiple comparison (a) or two-way analysis of variance with Bonferroni comparison (b). DMSO, dimethylsulphoxide; OEA, N-oleoylethanolamine; PPARa, peroxisome proliferator-activated receptor-a; wt, wild-type. (Figure 1 ), a classical PPARa agonist, although it lacked the efficacy of fenofibrate in the PPARa reporter gene assay (Figure 2) . Furthermore, assessment of the in vivo effects of OEA indicated that the protective effects of three dailyrepeated doses on infarct volume in a mode of stroke were lost in the PPARa gene-disrupted transgenic mouse (Figure 3 ).
The synthetic high-affinity cannabinoid agonist WIN 55212-2 displayed higher PPARa-binding affinity than OEA, although with biphasic effects on PPARa gene-transcription activity. WIN 55212-2 has also been found to display biphasic effects on CB receptors. For example, CB 1 -evoked voltage-dependent currents in retinal cones were enhanced by low concentrations (o1 mM) and inhibited by high concentrations (41 mM) of WIN 55212-2 (Fan and Yazulla, 2003) . This novel discovery that WIN 55212-2 has the ability to bind to and activate PPARa might provide a new way to explain, at least in part, its complex biological profile.
Although widely accepted as an endocannabinoid, anandamide has also been found to activate TRPV1 receptors (Zygmunt et al., 1999) and PPARg (Bouaboula et al., 2005; O'Sullivan et al., 2005) . By using the ligand binding and transactivation assays (Figures 1 and 2) , anandamide was further identified as a weak PPARa ligand. These multiple receptor targets of anandamide might confound its effects in various biological systems. For example, anandamide might induce apoptosis in the HeLa cells via TRPV1 (Contassot et al., 2004) , which could obscure its effects on PPARatranscription activity. Since these receptors and related pathways have different distributions in the body, anandamide effects in vivo could be expected to display tissue specificity. This is consistent with the manifold effects evoked by anandamide in the CNS and periphery. For example, it controls pain initiation, secretion of pituitary hormones, wake/sleep cycles, thermogenesis and appetite in the brain; in the cardiovascular system, anandamide profoundly decreases blood pressure and heart rate, reduces sympathetic tone due to inhibition of noradrenaline release and induces vasodilatation; in the immune system, anandamide supresses interleukin-2 transcription and secretion, stimulates interleukin-6 synthesis and inhibits tumour necrosis factor-a production Finazzi-Agro, 2002, 2003) .
The putative endocannabinoids, noladin ether and virodhamine, were found to show similar binding and transcriptional activity at PPARa as anandamide. Although these three agents are all arachidonic acid derivatives, they exhibit dissimilar affinities and efficacies for CB 1 and TRPV1 receptors (Duncan et al., 2004; Steffens et al., 2005) . In addition, we observed that noladin ether and virodhamine were less toxic to HeLa cells than anandamide (data not shown).
Tetrahydrocannabinol, the main psychoactive component in the cannabis plant, on the other hand, was found to lack significant PPARa binding or transcription activation. THC has been shown to act on PPARg and stimulate adipocyte differentiation in cultured 3T3L1 cells, in common with other PPARg ligands (Bouaboula et al., 2005; O'Sullivan et al., 2005) .
In vivo effects of cannabinoids: mechanisms of neuroprotection On the basis of in vitro assays of receptor occupancy and gene transcription, we identified that the synthetic cannabinoid WIN 55212-2 and the endogenous cannabinoid-like compound OEA were both capable of PPARa activation (Figures 1  and 2 ). We chose to investigate next whether these agents had PPARa agonist activity in vivo. Thus, although virodhamine, noladin and anandamide exhibited similar potency to OEA in competing for CPA binding to the PPARa LBD (Figure 1b) , and evoked similar gene-transcription responses in the reporter gene assay (Figure 2) , OEA was chosen for further investigation to avoid the potential for CB 1 or CB 2 cannabinoid receptor activation (Lin et al., 1998) and subsequent neuroprotective effects (Nagayama et al., 1999) . In pilot experiments for another study, we have observed that OEA administration leads to a marked increase in tissue levels of OEA, without alterations in anandamide levels (manuscript in preparation). Thus, while it is possible that fatty acid amide hydrolase-mediated hydrolysis of OEA, and the subsequent production of oleic acid, contributes to the activation of PPARa in intact systems, the use of fatty acid amide hydrolase-null is complicated by the elevations of multiple ECLs, including 10-fold increased levels of anandamide (an agonist at CB 1 , CB 2 , PPARa and PPARg receptors) and 20-fold increased levels of OEA (an agonist at PPARa receptors) (Clement et al., 2003) .
Furthermore, from the amounts of OEA administered, calculated to be 0.9 nmol per mouse based on a 30 g mouse, this could conceivably provide a plasma concentration of 0.5 mM, which is considerably less than circulating plasma FFA levels (B400 mM), approximately one-quarter of which is oleate (Seo et al., 2002) . It seems unlikely, therefore, that any action of exogenous OEA is mediated exclusively through fatty acid amide hydrolase-mediated hydrolysis to oleate.
In in vivo models, OEA and WIN 55212-2 were found to increase lipolysis significantly in mice, while noladin ether showed a strong trend towards enhancement (Figure 4a ). The lipolytic effect of OEA has previously been confirmed to function through PPARa (Guzman et al., 2004) . The lipolytic effect of WIN 55212-2, which was greater than the effects caused by other cannabinoids, might also be due to PPARa activation, despite being apparently less effective in the in vitro model (Figure 2) . A preliminary study with PPARa-null mice failed to show a significant elevation of plasma FFA following WIN 55212-2 administration (data not shown).
In the mouse stroke model, both fenofibrate (Deplanque et al., 2003) and OEA ( Figure 3 ) were found to have neuroprotective activities through PPARa, since they were unable to alter infarct volume in PPARa-deficient mice. Since the neuroprotective effects of PPARa were suggested to be independent of its well-known lipid-lowering effects (Deplanque et al., 2003) , antioxidant and anti-inflammatory mechanisms might underlie PPARa-dependent neuroprotection. A likely route for PPARa regulation of inflammatory responses is via repression of NFkB signalling (Staels et al., 1998) . The NF-kB pathway plays an important role in the immune system and is generally thought to exacerbate brain damage in ischaemic stroke. In mouse cerebral cortex, the NF-kB inhibitory protein IkBa was induced by OEA treatment ( Figure 4b ) and thus would be expected to restrict activity in the NF-kB pathway, inhibition of which has been demonstrated to reduce brain damage in several ischaemic stroke models (Salminen et al., 1995; Yang et al., 1995; Schneider et al., 1999) . Consistent with these findings, expression of the NF-kB-regulated COX-2 gene was found to be reduced by OEA treatment. Inhibition of COX-2 might contribute to OEA neuroprotection against stroke, since this enzyme is responsible for the production of prostaglandins that can potentiate pain and inflammation. The expression of COX-2 is generally found to be upregulated after stroke (Miettinen et al., 1997; Nogawa et al., 1997) , indicating a potential route for therapeutic intervention following such an insult. Although its role in cerebral ischaemic damage in man is unclear, inhibition of COX-2 expression can reduce the infarct volume and neuronal damage in stroke models (Iadecola et al., 2001) . For example, selective inhibition of COX-2 has been shown to reduce markedly global ischaemiaevoked hippocampal neuronal death (Nakayama et al., 1998) . However, given the network of genes that the NF-kB pathway is known to influence in the CNS, including neural cell adhesion molecules, amyloid precursor protein, m-opioid receptors, brain-derived neurotrophic factor, manganesedependent superoxide dismutase and Ca 2 þ /calmodulindependent protein kinase II (O'Neill and Kaltschmidt, 1997) , it is unlikely that COX-2 is solely responsible for PPARa-regulated neuroprotection.
There is evidence that CB 1 receptor-mediated neuroprotection might also be mediated, at least in part, through the NF-kB pathway (Panikashvili et al., 2005) , and so the possibility exists of generating/developing compounds with dual CB 1 /PPARa activity which converge at the level of cellular regulation through this important transcription factor.
Implications of PPARa as a target for cannabinoids
Our results, which show that multiple cannabinoid receptor ligands are also agonists at PPARa nuclear receptors, raise the issue that PPARa seems less fastidious with regard to ligand structures than cell-surface 7-transmembrane receptors (such as CB 1 or CB 2 ) or transmitter-gated channels like TRPV1. The large ligand-binding pocket of PPARa, which is able to accommodate a wide variety of fatty acid-derived molecules, is presumably the reason underlying such ligand promiscuity (Wang et al., 2004) .
Intriguingly, there appear to be differential effects of cannabinoid ligands on PPARs, in which THC appears to be a PPARg-selective ligand (Figures 1 and 2 ; O'Sullivan et al., 2005) , while WIN 55212-2 is able to activate both PPARa and PPARg (Figures 1 and 2 , and data not shown). It is tempting to speculate, therefore, that this variation may explain, at least in part, the variation in cannabinoid action in vivo.
Cannabinoid ligands are generally thought to have the ability to control appetite (Cota et al., 2003a) , while many hypolipidaemic drugs are identified as PPARa ligands. On the other hand, some cannabinoids, such as THC and anandamide, were found to stimulate adipocyte differentiation through PPARg (Bouaboula et al., 2005; O'Sullivan et al., 2005) . Since PPARa and PPARg play divergent roles in lipid homeostasis, agonists with dual or triple PPAR and CB receptor activities may have potential in dyslipidaemia therapy by targeting both CNS and periphery pathways. Alternatively, the discovery of PPAR-selective cannabinoids may lead to the development of new antidiabetic and hypolipidaemic drugs. Since OEA was only neuroprotective following repeated treatment in advance of ischaemic challenge, it could be argued that OEA, or agents working through the same mechanism, would not be practically useful as stroke medicines. However, there are populations of patients at increased risk of stroke (for example, following repeated incidence of transient ischaemic attacks) who could benefit from prophylactic treatment. The ability of OEA, given as a repeated treatment after ischaemia, to attenuate or reverse brain damage was not determined in the present study.
In summary, the data presented here provide strong evidence that selected cannabinoids (WIN 55212-2, OEA, noladin ether and virodhamine) are PPARa agonists, and suggest a novel means by which the multiple effects of cannabinoids, in both the CNS and periphery, could be brought about. In addition to its well-recognized role in lipid metabolism, PPARa activation showed obvious beneficial effects in ischaemic brain damage, which is likely to be connected with its anti-inflammatory action through the NF-kB pathway. These discoveries not only broaden the potential use of cannabinoids as therapeutic agents, but also support PPARa as a new target for neuroprotective treatment.
